Thera-SAbDab

TORIPALIMAB

> Structural Summary

Therapeutic	Toripalimab
Target	PDCD1
Heavy Chain	QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS
Light Chain	DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK
100% seqID Fv Structure	6jbt [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	6jbt [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2018
INN Year Recommended	2019
Companies Involved	Fudan University, Peking University, Shanghai Junshi Biosciences, Sun Yat-Sen University
Conditions Approved	Malignant melanoma
Conditions Active	Nasopharyngeal cancer, Oesophageal cancer, Biliary cancer, Gastric cancer, Non-small cell lung cancer, Solid tumours, Urogenital cancer, Head and neck cancer, Alveolar soft part sarcoma, Breast cancer, Cancer, Liver cancer, Lymphoma, Neuroendocrine tumours, Renal cancer
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]